330 related articles for article (PubMed ID: 34193230)
1. Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies.
Hanel W; Epperla N
J Hematol Oncol; 2021 Jun; 14(1):104. PubMed ID: 34193230
[TBL] [Abstract][Full Text] [Related]
2. When to Use Targeted Therapy for the Treatment of Follicular Lymphoma.
Nastoupil LJ
Curr Hematol Malig Rep; 2021 Feb; 16(1):45-51. PubMed ID: 33797691
[TBL] [Abstract][Full Text] [Related]
3. Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs.
Matasar MJ; Luminari S; Barr PM; Barta SK; Danilov AV; Hill BT; Phillips TJ; Jerkeman M; Magagnoli M; Nastoupil LJ; Persky DO; Okosun J
Oncologist; 2019 Nov; 24(11):e1236-e1250. PubMed ID: 31346132
[TBL] [Abstract][Full Text] [Related]
4. Advancements in the Management of Follicular Lymphoma: A Comprehensive Review.
Merryman R; Mehtap Ö; LaCasce A
Turk J Haematol; 2024 May; 41(2):69-82. PubMed ID: 38660754
[TBL] [Abstract][Full Text] [Related]
5. Follicular lymphoma: The long and winding road leading to your cure?
Gordon MJ; Smith MR; Nastoupil LJ
Blood Rev; 2023 Jan; 57():100992. PubMed ID: 35908982
[TBL] [Abstract][Full Text] [Related]
6. Follicular Lymphoma: a Focus on Current and Emerging Therapies.
Cahill KE; Smith SM
Oncology (Williston Park); 2022 Feb; 36(2):97-106. PubMed ID: 35180337
[TBL] [Abstract][Full Text] [Related]
7. Novel Therapy Approaches to Follicular Lymphoma.
Northend M; Townsend W
Drugs; 2021 Mar; 81(4):453-469. PubMed ID: 33616890
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapies in mantle cell lymphoma.
Hanel W; Epperla N
J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapies for Follicular Lymphoma.
Girard J; Karimi Y; Carty S; Wilcox R; Kaminiski M; Malek S; Phillips T
Curr Hematol Malig Rep; 2021 Feb; 16(1):25-31. PubMed ID: 33754292
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory Agents in Follicular Lymphoma.
Ysebaert L; Morschhauser F
Hematol Oncol Clin North Am; 2020 Aug; 34(4):715-726. PubMed ID: 32586576
[TBL] [Abstract][Full Text] [Related]
11. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.
Matarasso S; Assouline S
Future Oncol; 2023 Oct; 19(31):2083-2101. PubMed ID: 37882361
[TBL] [Abstract][Full Text] [Related]
12. Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade.
Apostolidis J; Mokhtar N; Al Omari R; Darweesh M; Al Hashmi H
Hematol Oncol; 2020 Aug; 38(3):213-222. PubMed ID: 31891210
[TBL] [Abstract][Full Text] [Related]
13. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
14. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
Abramson JS; Ghosh N; Smith SM
Am Soc Clin Oncol Educ Book; 2020 May; 40():302-313. PubMed ID: 32421455
[TBL] [Abstract][Full Text] [Related]
15. Thinking "outside the germinal center": Re-educating T cells to combat follicular lymphoma.
Kambhampati S; Shouse G; Danilov AV
Blood Rev; 2023 Sep; 61():101099. PubMed ID: 37173225
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
17. Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma.
Chin CK; Nastoupil LJ
Hematol Oncol Clin North Am; 2020 Aug; 34(4):743-756. PubMed ID: 32586578
[TBL] [Abstract][Full Text] [Related]
18. Targeted Therapy in Follicular Lymphoma: Towards a Chemotherapy-Free Approach.
Chen CJ; Choi MY; Heyman BM
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760453
[TBL] [Abstract][Full Text] [Related]
19. Individualized management of follicular lymphoma.
Bai B; Huang HQ
Chin Clin Oncol; 2015 Mar; 4(1):7. PubMed ID: 25841714
[TBL] [Abstract][Full Text] [Related]
20. Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
Chiu H; Trisal P; Bjorklund C; Carrancio S; Toraño EG; Guarinos C; Papazoglou D; Hagner PR; Beldi-Ferchiou A; Tarte K; Delfau-Larue MH; Morschhauser F; Ramsay AG; Gandhi AK
Br J Haematol; 2019 Apr; 185(2):240-253. PubMed ID: 30767211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]